Ascendiant Capital Maintains Buy on Surgepays, Raises Price Target to $3.75

Benzinga Newsdesk www.benzinga.com Positive 83.6%

Neg 0% Neu 0% Pos 83.6%

Ascendiant Capital analyst Edward Woo maintains Surgepays (NASDAQ:SURG) with a Buy and raises the price target from $3.5 to $3.75.